ERBB2 and neoplasm: Despite the investigation of multiple biomarkers to predict trastuzumab’s benefit (i.e., growth factor receptor signaling cascades, tumor microenvironment, tumor heterogeneity), up to now, a HER2 status remains the only validated biomarker in clinical practice [18,19].